Cargando…
Risk factors for progression to acute respiratory failure after casirivimab and imdevimab administration: A retrospective study
BACKGROUND: Casirivimab and imdevimab are effective in preventing hospitalization in outpatients with coronavirus disease 2019 (COVID-19); however, disease progression after casirivimab and imdevimab administration has been reported. This study aimed to elucidate the risk factors for disease progres...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Japanese Respiratory Society. Published by Elsevier B.V.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110271/ https://www.ncbi.nlm.nih.gov/pubmed/35589514 http://dx.doi.org/10.1016/j.resinv.2022.04.005 |